Texas Oncology Available To Patients Impacted By Harvey

coapharm2017-08-31T15:10:17+00:00August 31, 2017|

Gilead’s $11.9 Billion Purchase of a Groundbreaking Cancer Therapy Could Drag it Into a New Debate on Prices

coapharm2017-08-30T17:02:28+00:00August 30, 2017|

Bivarus and Community Oncology Alliance Collaborate to Improve Oncology Patient Experience

coapharm2017-08-29T17:56:05+00:00August 29, 2017|

Price tag fears cast shadow over ‘revolutionary’ leukemia drug

coapharm2017-08-29T17:52:46+00:00August 29, 2017|

Pharma advertising skyrockets while other categories decline

coapharm2017-08-29T17:50:09+00:00August 29, 2017|

Gilead-Kite: A Breakthrough. A $12 Billion Deal. Another Expensive Drug

coapharm2017-08-29T17:46:29+00:00August 29, 2017|

Breakthrough cancer drug could be astronomical in price

coapharm2017-08-23T19:23:38+00:00August 23, 2017|

Diplomat Sees Declining DIR Fee Impact—and Perhaps Readies a PBM Strategy

coapharm2017-08-16T18:52:33+00:00August 16, 2017|

Trump tweets up a storm on drug prices but delivers little change

coapharm2017-08-16T18:51:09+00:00August 16, 2017|

Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration

coapharm2017-08-16T18:48:26+00:00August 16, 2017|